Episode 272: Genomics for Rare Diseases With Katherine Stueland

Chadi sits down with Katherine Stueland, President and CEO of GeneDx, to explore how genomic sequencing is transforming the diagnosis of rare diseases—especially for pediatric patients who often endure years searching for answers. She discusses the company’s work analyzing the full genome to uncover gene–disease correlations, its efforts to bring advanced genetic testing directly into pediatricians’ offices through education and access initiatives, and how its massive rare-disease dataset is helping clinicians deliver faster, more precise diagnoses. The conversation also looks ahead to the expanding role of genomics in adult conditions such as neurodegenerative diseases, the potential of partnerships with biopharma, and how AI-driven analysis of large genomic datasets is accelerating discovery and precision medicine.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. https://www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. https://www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Transcript

SPEAKER_01 0:12

Folks, it's Healthcare Unfiltered, and it's your host, Shadi Nabhan. Thank you for joining me on Healthcare Unfiltered. It is our sixth year of this podcast, and without you, this podcast could never have continued for that long. Today's podcast is with an amazing, inspiring leader, Katherine Stuland, who is the Chief Executive Officer of Gene DX. She joined Gene DX in 2021, taking the full-time job at the top job of Gene DX, and her career is inspiring. It's amazing. If you just have seen the transformation that has occurred at Gene DX over the past five years, it's a testament to her leadership as well as to her ability to bring the team together to make sure that her constituents are served properly. Catherine, uh again, you can read a lot about her on the website. She has dedicated her career to transforming healthcare by leading patient-centric businesses. You are going to hear a lot about this from my interview with her. And I've asked Catherine to come on the show to explain to us a little bit about what Gene DX is doing, because the focus of the company is mainly on rare diseases, mainly in the pediatric patient population. But what is next? What are the challenges? What are the barriers? And what does it look like? Well, how does the path forward look like for uh Gene DX under the leadership of Catherine? Uh, I'm really very thankful that Catherine has joined the Healthcare Unfiltered podcast, and she's gonna share her insights with us. And uh folks, you can always uh let me know what you think about this podcast episode and other podcast episodes by following me on Twitter, by uh following me on Instagram, on YouTube, Facebook, and by subscribing to the show, letting your friends and colleagues know about the podcast, and sharing your views and ideas and opinions. Also, check out my books, The Cancer Journey: Understanding, Diagnosis, Treatment, Recovery, and Prevention, and Toxic Exposure, the true story behind the Monsanto Trials and the Search for Justice. Two more books coming out in 2026. One, AI and Cancer Care, When Machines Meet, Modern Medicine. And my first fiction ever that's coming in late 2026. Title is yet to be determined. So, folks, check out all of this, and you can find a lot of this information on my website, shaddinabhan.com. Catherine, thank you so much for your leadership, for your inspiration, inspiring journey, and thank you for coming on the show. And folks, without further ado, Catherine Stuland on Healthcare Unfiltered. Well, folks, I'm super excited today because uh I have a dear friend and an amazing leader in the world of oncology and genomics, and actually in genomics, not just oncology, everywhere. Um, Catherine Stuland, thank you so much for joining me on Healthcare on Filtering.

SPEAKER_00 3:21

It is so good to see you, and I'm thrilled to be here.

SPEAKER_01 3:25

It's your first time on the show, but it won't be last, right? We're gonna make sure we always follow the updates from you.

SPEAKER_00 3:31

Of course, of course. I can't say no to you.

SPEAKER_01 3:34

So, Catherine, uh obviously you have an amazing leadership role as the chief executive officer of Gene DX. So, and I have followed your your career path for many years. It's very inspiring and it's just amazing to see. But take us a bit back. How did you all start? Uh, how did you start and until you assumed the top role at Gene DX?

SPEAKER_00 3:58

You know, the my career started on the therapeutic side of things. I worked um on a few different therapeutics areas, um, HIV and AIDS worked on the first protease inhibitor to be approved by the FDA, um, did some work in um mental health, so worked on the FDA approvals of Selexa and Lexapro and Namenda for Alzheimer's disease. Um, and then got into the more dynamic world of biotech, um, worked on the first cancer immunotherapy to get approved by the FDA, which um is where I had the pleasure of getting to know and working with you. Um and shortly thereafter, um, there was a decision made by the Supreme Court that you couldn't patent DNA. Um, and it was centered around the what I like to call the celebrity genes, BRCA1 and II. Everyone knows them. Um, Angelina Jolie did us a world of good by coming out and talking about her experience with BRCO 1 and 2 and decisions that she made to preserve her health. Um, but that Supreme Court decision fundamentally changed um the way that genomic information could be utilized and accessed and put to work, not just for diagnosis, but for therapeutics as well. So I stepped into the genomics world and spent about seven and a half years driving the growth strategy of a company called Invite. And that's what led me to Gene DX in 2021.

SPEAKER_01 5:34

And um what what what what was the, you know, anytime when you transition roles, there's something that excites you about a new role? Take us back in 2021 when they were you're looking at this role, because it's no easy feat, right, to take on a role like this. What were what were you looking towards? And then maybe uh what what surprised you the most after you assumed the role?

SPEAKER_00 5:59

So I I got a call asking if I would be interested in being CEO of Gene DX. And um, I was really clear that I did not want to be a CEO, that I'm a really good number two person, um, and just support the the CEO and everything that they're doing. But uh but I said yes uh when when asked. And you know, I surprised myself in that moment, but I I took a step back um and I said, why would I want to do this? Well, one, there aren't that many women CEOs in biotech. Um there was this headline at JP Morgan a few years before that said there is there's more biotech CEOs named Mike than there are women biotech CEOs. So that stuck with me and I kept encouraging other women to do it. Um, but when I got the call, I said yes. Um so that was that that felt very aligned with me. You know, I I felt like I've been advocating for this, but now I should actually step into the arena. Um, I did take a look back to say when I first got into the genomics world, what excited me the most, and it was being able to run a genome on every baby at birth, this whole concept of let's sequence everyone, let's use that information as early as possible and fundamentally shift the way that disease is diagnosed. Um and so Gene DX was further along with a genome than anyone else was in the space. So that seemed like a really exciting opportunity as well. Um, so as I started exploring it and then got the job and started to explore it from the inside, um I realized I stepped into what I think is probably the best job in all of biotech. You've got this um industry-leading technology. Um, the prior owners had invested in the data. They invested in exome and genome technology ahead of the market. And so we had the raw data and we had the technology. Um, so my job is to bring a team together, figure out how to support that team, figure out how to get capital to fund it, um, and then see how many families we could impact as quickly as possible by using an exome or a genome to diagnose disease. So it's been a really meaningful five years. I'll be entering year five um in a few months. Um, and in many ways, we're just getting started.

SPEAKER_01 8:39

So what what does a day looks like? What does a day look like in the life of the GX CEO?

SPEAKER_00 8:47

Uh it always starts with um with some breath work in the morning.

SPEAKER_01 8:54

You meditate?

SPEAKER_00 8:55

I do. I do. I feel like um if I run immediately into my day, it's harder than catch your breath. So it's about three minutes um lay in bed and and breathe a little bit. So that's one that's one piece of it. I exercise six or seven times a week. So exercise in the morning also is helpful in terms of like just getting me in um, I don't know, the the right energetic place, um, clearing my mind. Um, and then I dive in. Um I I think part of what's kind of interesting, there's usually a lot of meetings, there's going to investor conferences, there's going to see customers, there's going to see policymakers. I feel like the best days are when I have like a little bit of all of those things. Um, it's really, really fun for me to spend time internally, but also um serving as our, you know, chief advocate for the mission. And um until a few years ago, the only people who really knew GDX were the very discerning uh geneticists in the world. So being able to now put us into this uh national spotlight and be able to advocate for not just the company, but ultimately for the families that we're aiming to serve is it's a privilege and I love doing it.

SPEAKER_01 10:21

Hey, when does your morning start?

SPEAKER_00 10:24

There's there's usually the the 3:30 wake up and then I try to get some more rest. Um, and then it's it's about a 5-30 wake up to get going.

SPEAKER_01 10:34

So, Catherine, there's a saying that sometimes uh I've read in in books and so on. Um a lot of people say for CEOs, it's lonely at the top. And I think what they some what they imply obviously is that you know, although it's sometimes you you have uh, you know, first of all, tell me how you react to because I hear it a lot, and how do you how do you surround yourself by the trusted people that you really want to make sure that when things are not well, you're able to can you really maintain that always optimistic look? Are you able like how do you really handle that?

SPEAKER_00 11:14

I try to keep a good poker face, but I would say my team would laugh at me if I said that I kept my composure all the time. Um uh so it is a lonely job. Like it at the end of the day, um, you are making decisions. I listen to a lot of people. Like I really want to take into account a lot of people's opinions when we're making a big decision. And we've made massive decisions. We were acquired by a company called Semaphore um back in 2022. That company was burning$90 million a quarter. Um, and the board gave me a mandate to make the company profitable as soon as possible. So we started doing business reviews and just saw an untenable path to keeping that entire business up and running. So we actually had to lay off uh the vast majority of their employees, all of their executives. Um, and so it was about 900 people or so that we had to lay off. Shutting down a company that bought you and their flagship businesses, those were monumental decisions that I was not anticipating we'd have to make. And so um when you're faced with, you know, how do you save this company? How do you preserve your capital? You know, on on the other side of this was also, I need to make sure that Gene DX is going to thrive. Um, this GDX was started at the NIH. It's it's uh it's doing something that no other company has done. Um, and so it really is um uh a force for good in the world and a very unique asset by way of our expertise, our data. Um, nobody else is doing this. So I felt this enormous pressure to keep Gene DX alive and thriving. And I also felt the weight of how do you make decisions about letting go of so many employees? And um, you know, as I said earlier, you ask people for their thoughts. You really want to um not be alone in the bunker in that moment because you're gonna miss things. Um but then you have to have the the deep breath and the moment of courage where you say, I believe this is the right thing. And um, sometimes those are pretty big leaps of faith. But um, you know, I I do think that um talking to other CEOs is incredibly helpful. Um, you you can't necessarily get into what it is you're solving for, but I do find um, you know, CEOs in our space, CEOs outside of our space, and just kind of like having a little bit of uh CEO to CEO therapy is helpful. Um and I frankly I went back to many of the CEOs I worked with in the past to say, I'm sorry for being so critical of you when I worked for you. Um it's so much harder than you will, you know, than most people will ever really imagine to carry the the stress of it. But you also get to make really amazing decisions, whether it's on strategy or benefits and culture. You know, we've we've been able to bring in new benefits that have helped some of our employees adopt a child. Um, and there's nothing more rewarding than getting the email from that employee saying, I want you to meet our new family member. So um it's all in balance. It's all in balance. And when you have such a great mission, um, it certainly makes the hard days um brighter.

SPEAKER_01 15:14

Absolutely. So tell my tell me a little bit about you mentioned GNDX, what it does. So what is it that GNDX, uh, if there's somebody out there who really doesn't know much about GNDX and what you do, what would you tell them? What is it that you do?

SPEAKER_00 15:30

So we diagnose more people with rare diseases than anyone in the world. And we do it using whole exome and whole genome sequencing. So a lot of people may remember um the the Human Genome Project back at the at the NIH that was now 25 years ago. Um, we've been able to take the promise of that and um put it within reach of anyone who might have a genetic disease. So um the work that we're doing today is diagnosing primarily children who have an unexplained illness. So they might have a rare form of epilepsy, of autism, they might have global developmental delay, or, you know, kind of a number of other really rare and ultra-rare diseases. So we go into the genome and we're able to figure out whether or not there's a mutation that is causing the disease. We're also finding new gene disease correlations and discoveries on almost a weekly basis now. Um, and so we're not only diagnosing disease, but in testing more patients and looking at the entirety of the genome, we're actually making more discoveries along the way as well.

SPEAKER_01 16:50

So, uh Catherine, is your focus only on rare non-oncology disease, or is this just part of the scope? In other words, folks with cancer, do you also are they part of your are they constituents of yours?

SPEAKER_00 17:03

So we primarily focus on um on genetic disease that is rare. Um, it usually is not cancer. Um we envision, though, as we think about our future, we do want to run a genome on everyone and be able to um uh do the job that a multi-gene panel might do today that would tell you if you um have a hereditary predisposition for cancer. So in the future, we do want to be able to inform cancer risk. Um, but today we're focused entirely on using an exoma genome in that pediatric population.

SPEAKER_01 17:41

And then are you seeing these this pediatric population undergo sequencing, or are you seeing that there's uh there are opportunities to educate the community to undergo, like in other words, percentwise, how many people undergo sequencing versus the folks that they should, but somehow they're not because they don't know, or their doctor doesn't know, or they don't have whatever that is?

SPEAKER_00 18:07

Yeah, the this is part of the problem that we're solving today. So, in the absence of knowing about this technology and that it's fast, it's affordable, and we're gonna be able to provide you an accurate answer as soon as 48 hours from a genome. Um absent that, it still takes five years on average for a child to get an accurate diagnosis. And so what we're trying to do, part of the problem today, um, if you think about it just through the lens of parent who has a child who's sick, you go to the pediatrician. And the pediatrician is not today doing, uh most aren't doing genetic testing. They usually say, let's wait and see, um, come back in in six months, see if there's another seizure. Um, they come back in and then they refer out to a specialist. And that specialist may be a developmental specialist or a pediatric neurologist. Um, historically, that doctor would then refer out to a geneticist. So it takes, in some parts of the country, it can take 12 to 24 months to actually get in to see a geneticist. So this journey of five years, it all adds up really quickly. Um, so what we're trying to do is take use of this testing um earlier in that family's journey. So that way when they go to the pediatrician, and just last summer, the American Academy of Pediatrics updated guidelines to say they should use this testing if they think there's global developmental delay. Um so they are um uh they now will be able to get testing in that pediatrician setting, which should help us diagnose more patients and earlier. Um to give you just a scope of how underutilized this is, in the NICU, fewer than 5% of babies actually get a genetic test. Um yet in the level four NICUs, um, we know that 60% of babies would benefit from a genetic test. So we're really trying to educate all of these clinicians, the non-genetics experts, which is something that we've seen in oncology work so effectively, right? We now see breast surgeons using um uh hereditary cancer testing. We've seen oncologists, of course, uh they've been using it now for a long time. Um, primary care doctors are offering hereditary cancer testing. So it's a similar sort of migration of we need the the non-uh genetics experts to start ordering this testing, and that's gonna completely change the way that we can get these kids on a healthier path a lot sooner.

SPEAKER_01 20:49

I I wanna step back a little bit just to get the stats right. You said less than 5% of NICU um of NICU patients who should undergo genetic testing undergo genetic testing. That's correct. I had to take a double take on this. Less than 5%. That's so so when you see this um is strategically when you put your strategy hat as the CEO, do you feel that it's education, education, education?

SPEAKER_00 21:18

That's a big part of it, but it's also workflow and implementation. Um, as you know, all of these folks are so busy. So um encumbering them with um a laborious order um process, it you know, burdening them with a really complicated um uh report that they have to understand. Um so from a technology standpoint, we need to make it easier for them to access it, easier for them to understand what to do. Um, and we really need to speak their language versus speaking the genetics language. So one is education, two is um Um is making the the user experience. I mean, we're at the end of the day, we're we're all used to one-click ordering. So we've got to make it super easy to access. Um and then the third part is making sure that policymakers and payers um are paying for it. And the good news is 80% of American lives today are covered. Um there's more and more state Medicaid programs that are covering our testing. It's in part because they're paying for the absence of testing today. They're paying to treat the symptoms, they're paying for an MRI when they don't need an MRI. So uh the the health economics support it just as importantly as the clinical outcomes support it.

SPEAKER_01 22:45

Right. So, but but when it comes to rare disease though, I mean, obviously you're uh I know where you focus is on rare diseases, but there are adults who also could have rare diseases. I mean, I don't know, uh ALS is an example. Uh I mentioned ALS because unfortunately last year I lost one of my dearest friends who's 50 years old to ALS, and we know how rare it is, and there's really nothing to do. Is this part of like, you know, your roadmap down the road? Or is it like what you know I mean, like a rare disease in non-pediatric population?

SPEAKER_00 23:18

And I'm so sorry for your loss. Um I I that is exactly why we need to move in to adults. Um so, and we're starting to move into that setting this year. Um, so we'll be in the adult neurology offices this year. Um we want to be able to help anyone at any age um get the earliest possible diagnosis, whether it's ALS, if it's um hypertrophic cardiomyopathy, um, if it is Alzheimer's disease, Parkinson's disease, um, we want to be able to get the earliest possible diagnosis because as you know, the earlier you diagnose, the the more options you have to be able to stay healthy or um be able to make decisions about um clinical trials, about FDA-approved therapies. Um so that is our mission. No matter what age, we want to be able to provide the earliest diagnosis with the most options for how to stay healthy.

SPEAKER_01 24:19

Yeah, that's amazing and so much needed. Now, um when you think of your, I mean, you do all of these testing. Do you do you work with biopharma who are interested in developing drugs? You know, you don't develop drugs, but frankly, you potentially could have all the targets that a company could develop drugs. Tell me a little bit about that and whether there's an intersection between what you do and what the drug development companies are trying to do.

SPEAKER_00 24:48

So uh biopharma partner partners are a key part of our strategy. Um, today, uh, when we're diagnosing disease, 95% of the time there's not an FDA-proof therapy for these families, um, which contributes to the reason why a doctor might not order the test because they want to know that there's something they can do. Um, the reality is absent in FDA-proof therapy, there's still clinical trials. There are still researchers out there that these parents can uh interact with. There are Facebook groups where they can connect with other families like them and be able to support one another. There's speech therapy, occupational therapy, but 95% of the time there's not an FDA in FDA-approved therapy, we want to flip that upside down. Um, and part of what we're doing, I mentioned earlier the data that we've amassed. So our data asset is called infinity. So for every patient that we're running, um, we're generating genotypic data, we're generating phenotypic data. So all of the clinic notes that come along with the order that's coming in, symptoms, family history, um, and other EMR-related data. And the totality of that information helps us um essentially pay it forward to the next patient. We're able to provide more accuracy the more patients that we that we run. So Infinity is comprised of um uh data from more than two and a half million patients, all in Red for Rare Disease. Yep. Um we have more than a million exomes and genomes worth of data. We've got 8 million health records. Um, 60% of the time, we're actually running mom and dad in addition to the child. Um, and we have uh a data set that is um diverse, it's highly representative of the US population. And so we want to take the totality of infinity and put it to work for patients with biopharma companies. How can we help them find the right target sooner? How do we help them recruit more patients faster to a clinical trial? Um, we were just meeting with a biopharma partner who was talking about the fact that they needed 400 patients for this one gene, and we pulled it up and we had more than 2,300 patients that we can reach out to and recontact with their permission. So we absolutely see partnering with biopharma on the discovery, on the development side of things as being a critical part of how we radically change the way that these rare disease patients are getting the help that they need. I would say the other um element that's really important, as we test more, we're actually finding that a lot more patients have a positive, a pathogenic or positive finding. And so these patient populations are actually three times, four times, five times larger than what was anticipated. We saw this on cancer testing as two. You test more, you find out that more people are affected. And having these larger patient populations, of course, becomes more attractive to investors. Um, and one of our partners, because we were able to show that their uh prevalence was three times larger, they secured a series C round, and now they're moving into that next phase. So it's this virtuous cycle of good as we test more, we diagnose more, we're finding these populations are larger, and that's becoming a catalyst for this entire genomic medicine ecosystem.

SPEAKER_01 28:29

That's really amazing. I I love that because we really need to figure out how do we really develop drugs for these patients. Are you thinking of expanding XUS? Is this something on the roadmap, I guess?

SPEAKER_00 28:42

It absolutely is. We want to be able to help any patient in any corner of the world. Um, and by taking Infinity, um, our data asset, um, and putting it into an interpretation platform as a service, what that means is if there is um a health system or health ministry in the UK or in the Middle East, they're buying sequencers from Illumina or Roche, we can actually put our interpretation layer and platform on top of it. So we very much believe because we have the largest rare disease data set, um, it shouldn't matter where you're where you're born. You should be able to benefit from our knowledge base. And so if it's a baby born in London or a baby born in LA, um, we want to make sure that we're all working from the same um uh the same knowledge base. So um we're excited about this approach to expanding internationally. Um we're gonna see how far we can get without setting up wet labs around the world. Um we want to see if we can do it in this decentralized way and work in partnership with um all of the sequencing companies.

SPEAKER_01 29:52

That'd be great because I think there are certain the prevalence of certain diseases vary geographically. So um just a couple more questions. One is that um, you know, in you know, as as a CEO, I presume you always are looking for innovation and new things. And I don't know if we can call AI a new thing anymore. I mean it's like every two seconds you hear the word AI. But still, it is something that you hear about uh every day. How do you take AI when you see something like this? Is this part strategically to integrate into what you're doing? Like are you are you implementing, I guess, AI in anything that Gene DX is doing?

SPEAKER_00 30:34

We are. Like most companies, I would say where we are furthest along is how do we work more efficiently? Um and you know, I think it's the the hard part is figuring out how do you optimize and pick the right companies and pilots, you know, if you think about trying to reduce denials. Um there's a lot of good companies out there that are trying to work on behalf of patients and companies like ours. And in diagnostics, you never get paid 100% of the time. Um best in class, you get paid about 70% of the time. Um, we're at about 55% of the time. So it's um it's in cases like that where we're trying to improve our business operations. I think when we talk about infinity, that's where it starts to get super interesting. So um we are we've been deploying AI in our interpretation platform. Um so that way we've got about 250 genetics experts on staff. Um, they have had to manually look up all of the various um uh information, genotypic and phenotypic, in our various databases. We've been around for 26 years. Now, what we've been able to do with um an AI feature called multi-score, multi-score is actually serving up for them the most likely variants to be causing disease. And so um that's a game changer for us in terms of um uh ensuring that there's standardization and working better, faster, um, and and cheaper along the way, that's gonna help us continue to lower our cost of goods. So um that's kind of the next level. How do we, with a growing data asset, continue um to automate and put AI to work so our our um our army of genetics experts are not so reliant on the manual approach. Um, and then the final part is how do we continue to enrich our data set? We just announced a deal with Komono Health where we're building the largest longitudinal rare disease data set together. Um, and that is going to be an opportunity for us using AI to be able to go back to pharma companies to say, here are the right targets that you should be looking at. Here's the true prevalence of these patients because we've been testing more and see how we might be able to disrupt the way that drugs are discovered and developed.

SPEAKER_01 33:06

Really amazing. Uh it's just inspiring to listen to you, Catherine, truly. Um, if I'm having this conversation with you in a couple of years from now, which we will, where do you want to see Gene DX in two years?

SPEAKER_00 33:19

I don't know. In two years, I want us to be um, I do want us to be dominating the world and bringing the power of our our platform to patients no matter where they're born. I want to see us meaningfully um uh um driving towards um universal newborn screening using our technology. Um, we've done the largest newborn screening study here in New York State. We've got the first state in Florida that now has funded newborn screening um for babies born in Florida. So um I didn't think we'd be as far on newborn screening as we are. So that really excites us. Um but most importantly, I I want to see us move from that five-year diagnostic odyssey to um uh under a year. Like no, no child should have to go through unnecessary disease progression. Um we can provide answers in as quick as two days. Um, so I I want to see us reduce that meaningfully and see some more wins on FDA approvals. Um, these kids are desperate for um for a breakthrough. These parents are the most inspiring parents. They are leaving their jobs in order to go find the researcher. So it's an area where they take um they they take the responsibility. They they are on um, unfortunately, in some cases, the the the clock is ticking for their child. And so they are absolutely motivated to try um to save their child and um fully knowing that it might be for another family that the breakthrough comes through. So these parents are the most inspiring parents. Um, and I'm hopeful that we can all work together um to reduce the burden a little bit so they don't have to completely upend their careers and their lives. Um, and we can do a better job being of service to them.

SPEAKER_01 35:28

Is there anything I should have asked you that I completely overlooked?

SPEAKER_00 35:33

I mean, you and I need to catch up on great restaurants in Chicago, but we'll do that offline and share some great restaurants in New York. But no, it's it I look at all of the amazing work, um Shadi, that you have done in oncology and that we were able to do together. And um, you know, my mom is turning 90 this year. She is on a cancer immunotherapy and she has never looked better. And um, she's healthy. She had a six-month time clock that was given to her. Um, it was three years ago, and she's doing great. So I look at all of the amazing work in cancer diagnostics, cancer treatments, and it's the most hopeful story. Um, there's still so many problems that we need to solve in the world of oncology, but the rare disease world, like we're we're doing our best to try to really bring forward as many breakthroughs as we can. Um, for us, it starts with the earliest possible diagnosis, but um, we view cancer as being such an amazing story of hope for all the rare disease patients.

SPEAKER_01 36:48

Well, thank you so much for everything you're doing. Thanks for your leadership and inspiration. And I look forward to always hearing the great things that uh you and Gene DX uh are doing. They are in safe hands under your leadership.

SPEAKER_00 37:01

Thank you so much.

SPEAKER_01 37:10

Thank you, folks, for listening to Healthcare Unfiltered. Thank you, Catherine, for joining me on the show. I uh I am amazed at the great work that you are doing and your team is doing at GindDX. Congratulations. And I hope that the next time we speak, things are going to be much, much better for patients that are in need. Folks, don't forget to subscribe to my show and let me know what you think. Uh, write a brief review. This will lead many folks to find healthcare unfiltered on their feed. Before I let you go, I'm gonna leave you with a saying by Rumi. Everyone has been made for some particular work, and the desire for that work has been put in every heart. Until next time, take care of it.